US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BioNexus Gene Lab Corp.

2.11

+0.12006.03%

Post-market: 2.10-0.0100-0.47%19:57 EST

Volume:9.02K

Turnover:18.99K

Market Cap:4.99M

PE:-1.65

High:2.16

Open:2.05

Low:2.04

Close:1.99

52wk High:15.60

52wk Low:1.98

Shares:2.36M

Float Shares:1.70M

Volume Ratio:0.10

T/O Rate:0.53%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.2783

EPS(LYR):-0.8970

ROE:-28.35%

ROA:-16.43%

PB:0.73

PE(LYR):-2.35

Loading ...

Overview Company News Filings

BioNexus Gene Lab Launches VitaGuard MRD Platform Across Southeast Asia

BioNexus Gene Lab Corp. Launches VitaGuard MRD Platform Across Southeast Asia

BRIEF-BioNexus Gene Lab Corp - Matthew L. Barsing Appointed As Chairman Of Chemrex Board - SEC Filing

BioNexus Gene Lab Corp - Matthew L. Barsing Appointed as Chairman of Chemrex Board - SEC Filing

THOMSON REUTERS

Chemrex Board Reshuffled Amid Governance Review at BioNexus Gene Lab Corp

Correction: Blue Gold Sets $15 Million Gold Trading Facility

MT Newswires Live

Bionexus Gene Lab Completes Strategic Investment In Fidelion Diagnostics Secures 15% Equity Stake In Global Ai-Oncology Platform

BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics

BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for Vitaguard™

THOMSON REUTERS

BioNexus Gene Lab Corp - Enters $500 Mln Equity Purchase Agreement

THOMSON REUTERS

BioNexus Gene Lab Corp - May Issue Shares to ARC Group International Over 36 Months

THOMSON REUTERS

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization

BRIEF-Bionexus Gene Lab Corp - To Pay $2 Million License Fee To Fidelion

BioNexus Gene Lab Corp - to Pay $2 Mln License Fee to Fidelion

THOMSON REUTERS

BioNexus Gene Lab Secures Exclusive Southeast Asia License for VitaGuard MRD Platform

Bionexus Gene Lab Corp Files For Mixed Shelf Of Up To $100 Million - SEC Filing

BioNexus Gene Lab Corp. Announces Date for Upcoming Annual Meeting of Stockholders

BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics

BioNexus Gene Lab Signs Southeast Asia MRD Commercialization Agreements

BioNexus Gene Lab Corp: Completion Is Conditioned on an Ip License Agreement Granting Bglc Exclusive Commercialization Rights Across Asean

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BGLC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BGLC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BGLC\",,,,,undefined,":{"symbol":"BGLC","market":"US","secType":"STK","nameCN":"BioNexus Gene Lab Corp.","latestPrice":2.11,"timestamp":1770411600000,"preClose":1.99,"halted":0,"volume":9019,"hourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.11,"latestTime":"19:57 EST","volume":2013,"amount":4299.6532,"timestamp":1770425826877,"change":-0.01,"changeRate":-0.004739,"amplitude":0.061611},"delay":0,"changeRate":0.060301507537688384,"floatShares":1700000,"shares":2363800,"eps":-1.278333,"marketStatus":"Market Closed","change":0.12,"latestTime":"02-06 16:00:00 EST","open":2.05,"high":2.16,"low":2.04,"amount":18989.6334717,"amplitude":0.060302,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.278333,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1689825600000,"exchange":"NASDAQ","adjPreClose":1.99,"preHourTrading":{"tag":"盘前","latestPrice":2.06,"preClose":1.99,"latestTime":"09:04 EST","volume":330,"amount":666.63993,"timestamp":1770386642218,"change":0.07,"changeRate":0.035176,"amplitude":0.020101},"postHourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.11,"latestTime":"19:57 EST","volume":2013,"amount":4299.6532,"timestamp":1770425826877,"change":-0.01,"changeRate":-0.004739,"amplitude":0.061611},"volumeRatio":0.1037227008886671},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BGLC\",,,,,undefined,":{"symbol":"BGLC","floatShares":1700000,"roa":"-16.43%","roe":"-28.35%","lyrEps":-0.897013,"volumeRatio":0.1037227008886671,"shares":2363800,"dividePrice":0,"high":2.16,"amplitude":0.060302,"preClose":1.99,"low":2.04,"week52Low":1.976,"pbRate":"0.73","psRate":"0.53","week52High":15.6,"institutionHeld":0,"latestPrice":2.11,"eps":-1.278333,"divideRate":0,"volume":9019,"delay":0,"ttmEps":-1.278333,"open":2.05,"prevYearClose":3.95,"prevWeekClose":2.5968,"prevMonthClose":2.5968,"prevQuarterClose":3.95,"fiveDayClose":2.5968,"twentyDayClose":3.9,"sixtyDayClose":5.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BGLC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-07","symbol":"BGLC","defaultRemindTime":1744032600000,"type":"split","dateTimestamp":1743998400000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2023-07-20","symbol":"BGLC","defaultRemindTime":1689859800000,"type":"split","dateTimestamp":1689825600000,"forFactor":1000000,"toFactor":83333,"ratio":12.000048000192}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BGLC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BGLC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BGLC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BGLC","date":"2026-02-06","current":-1.650587,"percent":0.998425,"low":-471.528444,"twenty":-6.570229,"median":-3.709154,"eighty":-3.090095,"high":-2.019632,"avg":-11.142071,"sd":35.707667,"marketCap":4704033},"quantilePoints":[{"date":"2023-07-06","current":-176.823166,"twenty":-176.823166,"median":-176.823166,"eighty":-176.823166,"marketCap":78173168},{"date":"2023-07-14","current":-471.528444,"twenty":-416.045263,"median":-332.820492,"eighty":-239.222096,"marketCap":208461782},{"date":"2023-07-21","current":-159.468227,"twenty":-406.064578,"median":-322.211103,"eighty":-162.939215,"marketCap":70500584},{"date":"2023-07-28","current":-76.673253,"twenty":-330.698614,"median":-184.702373,"eighty":-113.030056,"marketCap":33897092},{"date":"2023-08-04","current":-71.273729,"twenty":-322.211103,"median":-142.728572,"eighty":-75.23338,"marketCap":31509973},{"date":"2023-08-11","current":-41.036388,"twenty":-194.832842,"median":-107.9905,"eighty":-58.314869,"marketCap":18142105},{"date":"2023-08-18","current":-31.110617,"twenty":-192.581581,"median":-74.33346,"eighty":-38.156642,"marketCap":17505540},{"date":"2023-08-25","current":-37.115283,"twenty":-176.823166,"median":-67.314077,"eighty":-33.340847,"marketCap":20884287},{"date":"2023-09-01","current":-53.785707,"twenty":-159.468227,"median":-57.780238,"eighty":-37.115283,"marketCap":30264518},{"date":"2023-09-08","current":-32.711774,"twenty":-132.684778,"median":-52.370294,"eighty":-36.360396,"marketCap":18406490},{"date":"2023-09-15","current":-29.402853,"twenty":-113.030056,"median":-49.382198,"eighty":-32.837589,"marketCap":16544603},{"date":"2023-09-22","current":-30.510021,"twenty":-108.710436,"median":-43.916136,"eighty":-32.460145,"marketCap":17167592},{"date":"2023-09-29","current":-27.364657,"twenty":-89.200152,"median":-41.216373,"eighty":-30.696856,"marketCap":15397737},{"date":"2023-10-06","current":-22.646613,"twenty":-76.097304,"median":-39.788842,"eighty":-29.468277,"marketCap":12742955},{"date":"2023-10-13","current":-19.54214,"twenty":-74.513444,"median":-37.115283,"eighty":-27.175936,"marketCap":10996108},{"date":"2023-10-20","current":-16.607515,"twenty":-72.569616,"median":-34.441725,"eighty":-24.446566,"marketCap":9344833},{"date":"2023-10-23","current":-13.213669,"twenty":-72.137653,"median":-34.284457,"eighty":-23.753315,"marketCap":7435160},{"date":"2023-11-03","current":-11.826564,"twenty":-68.897938,"median":-32.903073,"eighty":-20.751847,"marketCap":6654654},{"date":"2023-11-10","current":-11.543482,"twenty":-64.858708,"median":-32.082701,"eighty":-19.55535,"marketCap":6495367},{"date":"2023-11-17","current":-10.694233,"twenty":-60.27764,"median":-30.822985,"eighty":-17.041576,"marketCap":6017506},{"date":"2023-11-24","current":-5.149203,"twenty":-57.887164,"median":-30.153992,"eighty":-12.992236,"marketCap":15928694},{"date":"2023-12-01","current":-5.425784,"twenty":-55.861647,"median":-29.402853,"eighty":-12.4808,"marketCap":16784279},{"date":"2023-12-08","current":-4.506257,"twenty":-52.653377,"median":-27.364657,"eighty":-11.581226,"marketCap":13939786},{"date":"2023-12-15","current":-3.860874,"twenty":-50.703252,"median":-26.735585,"eighty":-10.506141,"marketCap":11943340},{"date":"2023-12-21","current":-3.398254,"twenty":-50.137086,"median":-25.480617,"eighty":-7.056239,"marketCap":10512259},{"date":"2023-12-29","current":-2.99846,"twenty":-49.57092,"median":-23.752344,"eighty":-5.147406,"marketCap":9275523},{"date":"2024-01-05","current":-2.939062,"twenty":-48.124054,"median":-22.646613,"eighty":-4.622769,"marketCap":9091779},{"date":"2024-01-12","current":-2.868241,"twenty":-45.308557,"median":-20.74996,"eighty":-4.064426,"marketCap":8872700},{"date":"2024-01-19","current":-2.655208,"twenty":-43.814111,"median":-20.127294,"eighty":-3.952141,"marketCap":8213696},{"date":"2024-01-26","current":-3.095553,"twenty":-43.004079,"median":-19.54214,"eighty":-3.819752,"marketCap":9575873},{"date":"2024-02-02","current":-2.53941,"twenty":-41.324364,"median":-18.219783,"eighty":-3.215491,"marketCap":7855484},{"date":"2024-02-09","current":-2.558686,"twenty":-41.007054,"median":-13.213669,"eighty":-3.086415,"marketCap":7915113},{"date":"2024-02-16","current":-6.510941,"twenty":-40.449367,"median":-12.837799,"eighty":-3.06106,"marketCap":20141135},{"date":"2024-02-23","current":-4.706725,"twenty":-38.687965,"median":-12.583024,"eighty":-3.08413,"marketCap":14559921},{"date":"2024-03-01","current":-3.250331,"twenty":-38.156642,"median":-12.210298,"eighty":-3.095553,"marketCap":10054667},{"date":"2024-03-08","current":-4.405737,"twenty":-37.115283,"median":-11.590663,"eighty":-3.100979,"marketCap":13628835},{"date":"2024-03-15","current":-4.049349,"twenty":-35.857137,"median":-10.694233,"eighty":-3.152095,"marketCap":12526373},{"date":"2024-03-22","current":-4.310929,"twenty":-34.598992,"median":-10.38127,"eighty":-3.1698,"marketCap":13335552},{"date":"2024-03-28","current":-3.997947,"twenty":-34.347364,"median":-9.67326,"eighty":-3.234225,"marketCap":12367364},{"date":"2024-04-05","current":-3.563884,"twenty":-33.529569,"median":-6.510941,"eighty":-3.359532,"marketCap":11024621},{"date":"2024-04-12","current":-3.819603,"twenty":-33.017851,"median":-5.99692,"eighty":-3.39597,"marketCap":11819666},{"date":"2024-04-19","current":-5.702751,"twenty":-32.882655,"median":-5.425784,"eighty":-3.443945,"marketCap":14992778},{"date":"2024-04-26","current":-3.982383,"twenty":-32.743228,"median":-5.003144,"eighty":-3.456282,"marketCap":10469857},{"date":"2024-05-03","current":-4.096626,"twenty":-32.208516,"median":-4.750703,"eighty":-3.478442,"marketCap":10770207},{"date":"2024-05-10","current":-3.998512,"twenty":-31.305034,"median":-4.609633,"eighty":-3.536423,"marketCap":10512259},{"date":"2024-05-17","current":-3.78062,"twenty":-30.88177,"median":-4.409735,"eighty":-3.55686,"marketCap":10070567},{"date":"2024-05-24","current":-3.608171,"twenty":-30.822041,"median":-4.401739,"eighty":-3.562845,"marketCap":9611208},{"date":"2024-05-31","current":-2.817556,"twenty":-30.634577,"median":-4.297222,"eighty":-3.472959,"marketCap":7505221},{"date":"2024-06-07","current":-3.684446,"twenty":-30.082786,"median":-4.255895,"eighty":-3.45255,"marketCap":9814385},{"date":"2024-06-14","current":-2.931638,"twenty":-29.659033,"median":-4.216976,"eighty":-3.385163,"marketCap":7809105},{"date":"2024-06-21","current":-3.069598,"twenty":-29.500989,"median":-4.16618,"eighty":-3.266915,"marketCap":8176593},{"date":"2024-06-28","current":-3.151843,"twenty":-29.039249,"median":-4.14073,"eighty":-3.17466,"marketCap":8395672},{"date":"2024-07-05","current":-3.076894,"twenty":-28.268006,"median":-4.123596,"eighty":-3.152177,"marketCap":8196027},{"date":"2024-07-12","current":-3.354803,"twenty":-27.364657,"median":-4.091549,"eighty":-3.151893,"marketCap":8936302},{"date":"2024-07-19","current":-3.424446,"twenty":-27.30175,"median":-4.069909,"eighty":-3.152177,"marketCap":9121812},{"date":"2024-07-26","current":-3.245364,"twenty":-26.987215,"median":-4.059882,"eighty":-3.155965,"marketCap":8644786},{"date":"2024-08-02","current":-3.170415,"twenty":-26.532395,"median":-4.049349,"eighty":-3.155965,"marketCap":8445141},{"date":"2024-08-09","current":-2.860669,"twenty":-25.67183,"median":-4.031441,"eighty":-3.149986,"marketCap":7620061},{"date":"2024-08-16","current":-3.389234,"twenty":-25.135933,"median":-4.020016,"eighty":-3.138179,"marketCap":7474546},{"date":"2024-08-23","current":-3.442191,"twenty":-23.755257,"median":-3.998229,"eighty":-3.149986,"marketCap":7591336},{"date":"2024-08-30","current":-3.591285,"twenty":-23.527315,"median":-3.997375,"eighty":-3.150782,"marketCap":7920144},{"date":"2024-09-06","current":-3.339536,"twenty":-22.646613,"median":-3.986524,"eighty":-3.151843,"marketCap":7364943},{"date":"2024-09-13","current":-3.258879,"twenty":-22.149646,"median":-3.973647,"eighty":-3.149853,"marketCap":7187064},{"date":"2024-09-20","current":-3.289839,"twenty":-20.759396,"median":-3.917197,"eighty":-3.150517,"marketCap":7255341},{"date":"2024-09-27","current":-3.614496,"twenty":-20.740524,"median":-3.899057,"eighty":-3.151843,"marketCap":7971334},{"date":"2024-10-04","current":-3.435673,"twenty":-20.363314,"median":-3.883719,"eighty":-3.152095,"marketCap":7576962},{"date":"2024-10-11","current":-3.250732,"twenty":-19.891275,"median":-3.853911,"eighty":-3.152506,"marketCap":7169096},{"date":"2024-10-18","current":-3.023425,"twenty":-19.564157,"median":-3.809472,"eighty":-3.150517,"marketCap":6667798},{"date":"2024-10-25","current":-3.055199,"twenty":-19.54214,"median":-3.784642,"eighty":-3.136671,"marketCap":6737872},{"date":"2024-11-01","current":-3.073115,"twenty":-19.532703,"median":-3.733861,"eighty":-3.110193,"marketCap":6777383},{"date":"2024-11-08","current":-2.857222,"twenty":-19.108615,"median":-3.676038,"eighty":-3.095553,"marketCap":6301258},{"date":"2024-11-15","current":-5.724859,"twenty":-17.33095,"median":-3.666688,"eighty":-3.076894,"marketCap":5390298},{"date":"2024-11-22","current":-5.556929,"twenty":-16.607515,"median":-3.683511,"eighty":-3.08413,"marketCap":5232182},{"date":"2024-11-29","current":-4.413865,"twenty":-13.892438,"median":-3.75724,"eighty":-3.085752,"marketCap":4155919},{"date":"2024-12-06","current":-5.553113,"twenty":-13.185991,"median":-3.785346,"eighty":-3.093674,"marketCap":5228589},{"date":"2024-12-13","current":-4.963452,"twenty":-12.929958,"median":-3.814538,"eighty":-3.095859,"marketCap":4673388},{"date":"2024-12-20","current":-4.368067,"twenty":-12.81987,"median":-3.860874,"eighty":-3.09997,"marketCap":4112797},{"date":"2024-12-27","current":-5.100849,"twenty":-12.71167,"median":-3.883719,"eighty":-3.106414,"marketCap":4802755},{"date":"2025-01-03","current":-8.791474,"twenty":-12.59592,"median":-3.898381,"eighty":-3.1101,"marketCap":8277700},{"date":"2025-01-10","current":-6.240095,"twenty":-12.505963,"median":-3.911149,"eighty":-3.111625,"marketCap":5875424},{"date":"2025-01-17","current":-7.20378,"twenty":-12.406569,"median":-3.952872,"eighty":-3.119608,"marketCap":6782791},{"date":"2025-01-24","current":-6.740066,"twenty":-12.210298,"median":-3.982649,"eighty":-3.128629,"marketCap":6346177},{"date":"2025-01-31","current":-7.776266,"twenty":-11.826564,"median":-3.988431,"eighty":-3.135261,"marketCap":7321821},{"date":"2025-02-07","current":-7.346902,"twenty":-11.637843,"median":-3.997893,"eighty":-3.136671,"marketCap":6917549},{"date":"2025-02-14","current":-7.079741,"twenty":-11.543482,"median":-3.998512,"eighty":-3.139115,"marketCap":6666001},{"date":"2025-02-21","current":-6.703809,"twenty":-10.989898,"median":-4.026503,"eighty":-3.147705,"marketCap":6312038},{"date":"2025-02-28","current":-6.249637,"twenty":-10.725687,"median":-4.032163,"eighty":-3.150384,"marketCap":5884408},{"date":"2025-03-07","current":-7.041576,"twenty":-10.691717,"median":-4.05506,"eighty":-3.151578,"marketCap":6630066},{"date":"2025-03-14","current":-6.679002,"twenty":-10.444492,"median":-4.064198,"eighty":-3.152045,"marketCap":6288681},{"date":"2025-03-21","current":-5.438616,"twenty":-10.380327,"median":-4.083617,"eighty":-3.152424,"marketCap":5120783},{"date":"2025-03-28","current":-4.772623,"twenty":-10.379698,"median":-4.101544,"eighty":-3.165257,"marketCap":4493711},{"date":"2025-04-04","current":-4.47684,"twenty":-9.249398,"median":-4.128883,"eighty":-3.169097,"marketCap":4215213},{"date":"2025-04-11","current":-5.018321,"twenty":-8.826544,"median":-4.140855,"eighty":-3.16926,"marketCap":4725050},{"date":"2025-04-17","current":-3.068623,"twenty":-8.256773,"median":-4.14066,"eighty":-3.162069,"marketCap":4904709},{"date":"2025-04-25","current":-3.237229,"twenty":-7.825882,"median":-4.123596,"eighty":-3.152342,"marketCap":5174199},{"date":"2025-05-02","current":-3.023661,"twenty":-7.747642,"median":-4.091549,"eighty":-3.151313,"marketCap":4832845},{"date":"2025-05-09","current":-3.001181,"twenty":-7.705659,"median":-4.069909,"eighty":-3.136429,"marketCap":4796913},{"date":"2025-05-16","current":-2.417617,"twenty":-7.678943,"median":-4.059882,"eighty":-3.135743,"marketCap":5120301},{"date":"2025-05-23","current":-2.400652,"twenty":-7.648411,"median":-4.049349,"eighty":-3.114489,"marketCap":5084369},{"date":"2025-05-30","current":-3.291353,"twenty":-7.625512,"median":-4.032112,"eighty":-3.104603,"marketCap":6970796},{"date":"2025-06-06","current":-2.731484,"twenty":-7.611772,"median":-4.023259,"eighty":-3.095706,"marketCap":5785042},{"date":"2025-06-13","current":-2.472756,"twenty":-7.600704,"median":-3.998512,"eighty":-3.079788,"marketCap":5237080},{"date":"2025-06-20","current":-2.485481,"twenty":-7.540784,"median":-3.99784,"eighty":-3.068818,"marketCap":5264029},{"date":"2025-06-27","current":-2.298857,"twenty":-7.34194,"median":-3.987477,"eighty":-3.057438,"marketCap":4868777},{"date":"2025-07-03","current":-5.454484,"twenty":-7.346902,"median":-3.987477,"eighty":-3.055293,"marketCap":11552118},{"date":"2025-07-11","current":-5.123652,"twenty":-7.322094,"median":-3.99784,"eighty":-3.057383,"marketCap":10851445},{"date":"2025-07-18","current":-5.624142,"twenty":-7.27057,"median":-3.997607,"eighty":-3.057659,"marketCap":11911438},{"date":"2025-07-25","current":-4.13964,"twenty":-7.251487,"median":-3.998512,"eighty":-3.064292,"marketCap":8767393},{"date":"2025-08-01","current":-5.878628,"twenty":-7.251487,"median":-3.998512,"eighty":-3.067241,"marketCap":12450417},{"date":"2025-08-08","current":-4.801304,"twenty":-7.251487,"median":-4.026503,"eighty":-3.068623,"marketCap":10168739},{"date":"2025-08-15","current":-4.546817,"twenty":-7.20378,"median":-4.032163,"eighty":-3.069598,"marketCap":9629759},{"date":"2025-08-22","current":-3.503537,"twenty":-7.079741,"median":-4.030769,"eighty":-3.073115,"marketCap":10276534},{"date":"2025-08-29","current":-3.534163,"twenty":-7.05875,"median":-4.009264,"eighty":-3.076894,"marketCap":10366364},{"date":"2025-09-05","current":-3.485162,"twenty":-7.045011,"median":-3.998229,"eighty":-3.082683,"marketCap":10222636},{"date":"2025-09-12","current":-2.634084,"twenty":-6.982037,"median":-3.997375,"eighty":-3.069403,"marketCap":7726265},{"date":"2025-09-19","current":-3.491287,"twenty":-6.965626,"median":-3.98472,"eighty":-3.072412,"marketCap":10240602},{"date":"2025-09-26","current":-3.67504,"twenty":-6.948451,"median":-3.964911,"eighty":-3.074449,"marketCap":10779582},{"date":"2025-10-03","current":-3.283035,"twenty":-6.899981,"median":-3.914173,"eighty":-3.076472,"marketCap":9629759},{"date":"2025-10-10","current":-3.295285,"twenty":-6.881279,"median":-3.898381,"eighty":-3.082683,"marketCap":9665691},{"date":"2025-10-17","current":-3.160534,"twenty":-6.873265,"median":-3.876866,"eighty":-3.085752,"marketCap":9270440},{"date":"2025-10-24","current":-3.178909,"twenty":-6.864105,"median":-3.859705,"eighty":-3.086858,"marketCap":9324338},{"date":"2025-10-31","current":-3.178909,"twenty":-6.837771,"median":-3.814538,"eighty":-3.087618,"marketCap":9324338},{"date":"2025-11-07","current":-3.197284,"twenty":-6.816398,"median":-3.785346,"eighty":-3.089629,"marketCap":9378236},{"date":"2025-11-14","current":-2.76853,"twenty":-6.754569,"median":-3.781989,"eighty":-3.087618,"marketCap":8120618},{"date":"2025-11-21","current":-3.402632,"twenty":-6.714114,"median":-3.746807,"eighty":-3.086858,"marketCap":7815196},{"date":"2025-11-28","current":-3.551075,"twenty":-6.705336,"median":-3.684446,"eighty":-3.087472,"marketCap":8156141},{"date":"2025-12-05","current":-3.386818,"twenty":-6.703809,"median":-3.672269,"eighty":-3.089163,"marketCap":7778875},{"date":"2025-12-12","current":-3.332066,"twenty":-6.700374,"median":-3.655837,"eighty":-3.09337,"marketCap":7653119},{"date":"2025-12-19","current":-4.250524,"twenty":-6.698084,"median":-3.672269,"eighty":-3.095782,"marketCap":9762642},{"date":"2025-12-26","current":-4.271108,"twenty":-6.690451,"median":-3.683511,"eighty":-3.097274,"marketCap":9809919},{"date":"2026-01-02","current":-4.065271,"twenty":-6.679002,"median":-3.740334,"eighty":-3.099622,"marketCap":9337152},{"date":"2026-01-09","current":-4.013812,"twenty":-6.679002,"median":-3.78062,"eighty":-3.102791,"marketCap":9218960},{"date":"2026-01-16","current":-3.797684,"twenty":-6.663736,"median":-3.784642,"eighty":-3.110069,"marketCap":8722554},{"date":"2026-01-23","current":-3.313968,"twenty":-6.60267,"median":-3.781989,"eighty":-3.110193,"marketCap":7611551},{"date":"2026-01-30","current":-2.727334,"twenty":-6.583587,"median":-3.746807,"eighty":-3.100979,"marketCap":6264165},{"date":"2026-02-06","current":-2.048073,"twenty":-6.570229,"median":-3.709154,"eighty":-3.090095,"marketCap":4704033}],"updateTime":1770507116523},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BGLC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608026800","title":"BioNexus Gene Lab Launches VitaGuard MRD Platform Across Southeast Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2608026800","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608026800?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:11","pubTimestamp":1770153098,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp. has announced the regional deployment of its VitaGuard Minimal Residual Disease  platform, marking a significant expansion across Southeast Asia. The company is moving forward with initial rollouts in key medical hubs, aiming to establish routine MRD monitoring for solid tumor indications. To support this expansion, BioNexus has established Fidelion Diagnostics Pte. Ltd. as the commercialization vehicle outside China and has actively recruited experienced personnel. The initiative also includes partnerships with regional healthcare providers to integrate VitaGuard into standard care, positioning BioNexus to address the growing demand for affordable, AI-enhanced precision oncology in the region.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL5fJ4DN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGLC","BK4104"],"gpt_icon":0},{"id":"2606712863","title":"BioNexus Gene Lab Corp. Launches VitaGuard MRD Platform Across Southeast Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2606712863","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606712863?lang=en_us&edition=fundamental","pubTime":"2026-01-28 22:00","pubTimestamp":1769608849,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp. has announced the regional deployment of its VitaGuard Minimal Residual Disease  platform across Southeast Asia, marking a significant expansion of its precision diagnostics infrastructure. The company is transitioning VitaGuard from a technological innovation to a scalable oncology solution, aiming to replace costly legacy cancer monitoring systems in the region. As part of this initiative, BioNexus has established Fidelion Diagnostics Pte. Ltd. to manage intellectual property and commercialization outside China and is actively recruiting technical, operational, and commercial staff. The expansion also includes preparations for market entry with a regional diagnostics partner and the launch of upgraded global patent filings to support the platform’s growth.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL8WgD1P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","BGLC","BK4104","BK4588","LU0314104364.USD","LU2095319765.USD","IE00BKPKM429.USD","NDAQ","SG9999014021.USD","SG9999014039.USD","BK4585","SG9999014005.SGD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2593268446","title":"BRIEF-BioNexus Gene Lab Corp - Matthew L. Barsing Appointed As Chairman Of Chemrex Board - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2593268446","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593268446?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:55","pubTimestamp":1766530509,"startTime":"0","endTime":"0","summary":"BRIEF-BioNexus Gene Lab Corp - Matthew L. Barsing Appointed As Chairman Of Chemrex Board - SEC FilingDec 23  - BioNexus Gene Lab Corp BGLC.O:BIONEXUS GENE LAB CORP - MATTHEW L. BARSING APPOINTED AS CHAIRMAN OF CHEMREX BOARD - SEC FILINGSource text: [ID:n0001477932-25-009186]Further company coverage: BGLC.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2593446589","title":"BioNexus Gene Lab Corp - Matthew L. Barsing Appointed as Chairman of Chemrex Board - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2593446589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593446589?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:32","pubTimestamp":1766529147,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BGLC","BK4104"],"gpt_icon":0},{"id":"2593450004","title":"Chemrex Board Reshuffled Amid Governance Review at BioNexus Gene Lab Corp","url":"https://stock-news.laohu8.com/highlight/detail?id=2593450004","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593450004?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:21","pubTimestamp":1766528476,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp. Appoints New Chairman and Reconstitutes Chemrex Board Amid Governance Review. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL13jgcW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2588047603","title":"Correction: Blue Gold Sets $15 Million Gold Trading Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2588047603","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588047603?lang=en_us&edition=fundamental","pubTime":"2025-12-03 23:01","pubTimestamp":1764774076,"startTime":"0","endTime":"0","summary":"Blue Gold  said Wednesday that it has expanded its partnership with DL Hudson Dunes to add a $15 million facility to finance gold trades.The facility will fund purchases of gold from mines and licensed aggregators worldwide, with a target of two to three trades a month and projected profit margins of 1% to 5% per trade, the company said.DL Hudson Dunes will partner on each transaction to provide legal, compliance and commercial support for the trading operations, Blue Gold said.The company said it ultimately plans to move further into mining in West Africa and Latin America and to launch a fintech wallet and payment card by Q3, 2026, to support spending of its Standard Gold Coin.Shares of the company were up more than 1% in recent early trading on Wednesday.Price: 4.55, Change: -0.02, Percent Change: -0.44","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BGL","BGL.AU","BGLC","BK4104","BK7104","BK4017"],"gpt_icon":0},{"id":"2588044606","title":"Bionexus Gene Lab Completes Strategic Investment In Fidelion Diagnostics Secures 15% Equity Stake In Global Ai-Oncology Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2588044606","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588044606?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:09","pubTimestamp":1764770978,"startTime":"0","endTime":"0","summary":"Dec 3 (Reuters) - BioNexus Gene Lab Corp ::*BIONEXUS GENE LAB CORP. COMPLETES STRATEGIC INVESTMENT IN FIDELION DIAGNOSTICS; SECURES 15% EQUITY STAKE IN GLOBAL AI-ONCOLOGY PLATFORM AND EXCLUSIVE SOUTHE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nRSD3NbFjV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2588041193","title":"BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2588041193","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588041193?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:45","pubTimestamp":1764769516,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp. has completed a strategic equity investment in Fidelion Diagnostics Pte. Ltd., acquiring a 15% minority stake through a non-cash share swap. In return, Fidelion now holds approximately 16.6% of BioNexus Gene Lab Corp.'s issued and outstanding stock, aligning the interests of both companies. As part of the agreement, BioNexus Gene Lab Corp. also secured exclusive commercial rights to the VitaGuard Tumor-Nave Minimal Residual Disease  liquid biopsy platform for Southeast Asia via a licensing agreement, with the license fee payable over 24 monthly installments. The deal is designed to preserve financial strength, minimize dilution, and support BioNexus Gene Lab Corp.'s expansion in the precision oncology market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interprete","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL3sWBGT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","BGLC","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","BK4104","IE00B64PRP62.GBP","BK4588"],"gpt_icon":0},{"id":"2588188041","title":"BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for Vitaguard™","url":"https://stock-news.laohu8.com/highlight/detail?id=2588188041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588188041?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:45","pubTimestamp":1764769500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA1RP08D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2588605376","title":"BioNexus Gene Lab Corp - Enters $500 Mln Equity Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2588605376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588605376?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:05","pubTimestamp":1764680747,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80NA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2588053088","title":"BioNexus Gene Lab Corp - May Issue Shares to ARC Group International Over 36 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053088?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:05","pubTimestamp":1764680747,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80NA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BGLC","BK4104"],"gpt_icon":0},{"id":"2588011053","title":"BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011053","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588011053?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:05","pubTimestamp":1764680700,"startTime":"0","endTime":"0","summary":"SHERIDAN, Wyo., Dec.  02, 2025  (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC” or the “Company”), an emerging provider of precision oncology diagnostics with expanding operations across Southeast","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197900/0/en/BioNexus-Gene-Lab-Corp-Nasdaq-BGLC-Secures-500-Million-Equity-Facility-From-ARC-Group-International-to-Support-Expansion-of-Precision-Diagnostics-CDMO-Operations-and-Therapeutic-Co.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGLC","BK4215","BK4104","CDMO","EQR","BK4588","BK4143","BK4139","BK4585","ARC"],"gpt_icon":0},{"id":"2588977806","title":"BRIEF-Bionexus Gene Lab Corp - To Pay $2 Million License Fee To Fidelion","url":"https://stock-news.laohu8.com/highlight/detail?id=2588977806","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588977806?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:50","pubTimestamp":1764597034,"startTime":"0","endTime":"0","summary":"BRIEF-Bionexus Gene Lab Corp - To Pay $2 Million License Fee To FidelionDec 1 (Reuters) - BioNexus Gene Lab Corp BGLC.O:BIONEXUS GENE LAB CORP - TO PAY $2 MILLION LICENSE FEE TO FIDELIONSource text: ID:nGNX67xlVYFurther company coverage: BGLC.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2588720631","title":"BioNexus Gene Lab Corp - to Pay $2 Mln License Fee to Fidelion","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720631?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:04","pubTimestamp":1764594245,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2588720879","title":"BioNexus Gene Lab Secures Exclusive Southeast Asia License for VitaGuard MRD Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720879","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720879?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:00","pubTimestamp":1764594030,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp. has announced the execution of an Exclusive Intellectual Property License Agreement with Fidelion Diagnostics Pte. Ltd. for the VitaGuard minimal residual disease  liquid biopsy platform in Southeast Asia. The agreement grants BioNexus Gene Lab Corp. exclusive, perpetual rights to the VitaGuard MRD platform across the region. This license is a key condition for the completion of a previously announced Share Subscription and Shareholders' Agreement among BioNexus Gene Lab Corp., Fidelion Diagnostics, and Tongshu Gene, under which BioNexus Gene Lab Corp. will become a strategic shareholder in Fidelion Diagnostics, with Fidelion Diagnostics taking a minority stake in BioNexus Gene Lab Corp.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, invest","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL4KsN2X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","BK4104","LU0314104364.USD","BGLC","BK4585","BK4588","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2210149790.SGD"],"gpt_icon":0},{"id":"2584921884","title":"Bionexus Gene Lab Corp Files For Mixed Shelf Of Up To $100 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584921884","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584921884?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:07","pubTimestamp":1763572056,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp ::*BIONEXUS GENE LAB CORP FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 07-NOV-202522:15:55 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDbXvkVv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGLC","BK4104"],"gpt_icon":0},{"id":"2583684259","title":"BioNexus Gene Lab Corp. Announces Date for Upcoming Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2583684259","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583684259?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:30","pubTimestamp":1763155856,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp. will hold its Annual Meeting of Stockholders online on December 24, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL9pdyV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGLC","BK4104"],"gpt_icon":0},{"id":"2582737480","title":"BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2582737480","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582737480?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:32","pubTimestamp":1762954366,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp.  has entered into definitive agreements involving an equity investment with Fidelion Diagnostics Pte. Ltd. As part of the deal, BGLC will receive new shares representing at least 15% of Fidelion's fully diluted share capital. In exchange, Fidelion will receive newly issued, restricted shares equal to 19.9% of BGLC's pre-money outstanding shares. This cross-equity alignment is part of a broader collaboration to commercialize VitaGuard, a next-generation liquid-biopsy platform for minimal residual disease  testing across Southeast Asia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Ana","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL9W9Qn9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2582379236","title":"BioNexus Gene Lab Signs Southeast Asia MRD Commercialization Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2582379236","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582379236?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:00","pubTimestamp":1762952437,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp.  announced that it has entered into definitive agreements with Fidelion Diagnostics Pte. Ltd. and Tongshu Biotechnology  Co., Limited to commercialize VitaGuard, a tumor-nave liquid-biopsy platform for minimal residual disease  detection, in Southeast Asia. The agreements include a Share Subscription and Shareholders' Agreement, as well as plans for an IP License Agreement that will grant BGLC exclusive commercialization rights across ASEAN. BGLC is expected to lead regulatory submissions and commercialization efforts, with an initial focus on Singapore and Malaysia. The collaboration aims to support MRD testing development and commercialization in the region through aligned ownership, licensing, and operational support. Completion of the transaction is subject to satisfaction of certain conditions precedent.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL83YHr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BGLC","BK4104","LU2210149790.SGD","BK4588","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4585","NDAQ","LU2210150020.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582797853","title":"BioNexus Gene Lab Corp: Completion Is Conditioned on an Ip License Agreement Granting Bglc Exclusive Commercialization Rights Across Asean","url":"https://stock-news.laohu8.com/highlight/detail?id=2582797853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582797853?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:00","pubTimestamp":1762952407,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA6S22QG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BGLC","BK4104"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}]}}